Open AccessBORTEZOMIB INDUCED SUBCONJUNCTIVAL HEMORRHAGE
Author(s) -
Navin Patil,
Balaji Ommurugan,
Karthik S Udupa,
Karthik Rao
Publication year - 2017
Publication title -
asian journal of pharmaceutical and clinical research
Language(s) - English
Resource type - Journals
eISSN - 2455-3891
pISSN - 0974-2441
DOI - 10.22159/ajpcr.2017.v10i4.16907
Subject(s) - bortezomib , thalidomide , multiple myeloma , dexamethasone , lenalidomide , proteasome inhibitor , pharmacology , medicine , proteasome , adverse effect , chemistry , biochemistry
Many drugs are used in the treatment of multiple myeloma but Thalidomide, Lenalidomide, Bortezomib, dexamethasone and their combination remains the main stay of treatment. The molecular formula of bortezomib is C19H25BN4O4 and its chemical IUPAC name is [3-methyl-1-(3-phenyl-2-pyrazin-2-ylcarbonylamino-propanoyl) amino-butyl] boronic acid. Mechanisms by which it acts is usually by 26 SProteasome inhibition leading to degradation of anti-apoptotic proteins. Bortezomib is known to cause many side effects. So hence we report a rare case of Bortezomib induced subconjunctival hemorrhage in our tertiary care hospital.KEYWORDS: Bortezomib, Adverse effect, Proteosome inhibition, Subconjunctival Hemorrhage